Serotonergic basis of antipsychotic drug effects in schizophrenia

Biological Psychiatry

Volumn 44, Issue 11, 1998, Pages 1099-1117

  Lieberman, Jeffrey A ^a,b   Mailman, Richard B ^a,b   Duncan, Gary ^a,b   Sikich, Lin ^a,b   Chakos, Miranda ^a,b   Nichols, David E ^c   Kraus, John E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Antipsychotic drugs; Atypical; Clozapine; Dopamine; Neuroleptic; Raphe; Receptors; Schizophrenia; Serotonin; Striatum

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SERTINDOLE; ZIPRASIDONE;

CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DORSAL RAPHE NUCLEUS; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; NERVOUS SYSTEM DEVELOPMENT; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANTIPSYCHOTIC AGENTS; BRAIN; CORPUS STRIATUM; DOPAMINE; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RAPHE NUCLEI; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032401137     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00187-5     Document Type: Review

References (210)

1. Andén N.E., Corrodi H., Fuxe K., Hokfelt T. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Br J Pharmacol Chemother. 34:1968;1-7.
2. Andén N.E., Corrodi H., Fuxe K. Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J Pharmacol Exp Ther. 179:1971;236-249.
3. Andén N.E., Corrodi H., Fuxe K., Meek J.L. Hallucinogenic phenethylamines Interactions with serotonin turnover and receptors . Eur J Pharmacol. 25:1974;176-184.
4. Andreasen N.C., Rezai K., Alliger R., et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography. Arch Gen Psychiatry. 12:1992;943-958.
5. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 283:1995;55-62.
6. 2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm Gen Sect. 85:1991;19-29.
7. Arranz M., Collier D., Sodhi M., et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 346:1995;281-282.
8. Arranz M.J., Dawson E., Shaikh S., et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol. 4:1995;417-420.
9. Arranz M.J., Collier D.A., Munro J., et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 217:1996;177-178.
10. 3 like receptors in the rat medial prefontal cortex an electrophysiological study . Brain Research. 550:1991;181-191.
11. 3-like receptor supersensitivity and dopamine receptor subsensitivity in the rat medial prefrontal cortex after intraventricular administration of the neurotoxin 5,7-dihydroxytryptamine A microiontophoretic study . Neuroscience. 60:1994;453-462.
12. Ashcroft G.W., Crawford T.B.B., Eccleston D., et al. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet. ii:1966;1049-1052.
13. Azmitia E.C., Whitaker-Azmitia P.M. Awakening the sleeping giant Anatomy and plasticity of the brain serotonergic system . J Clin Psychiatry. 52:(suppl 12):1991;4-16.
14. 1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Res. 677:1995;181-192.
15. Baker M.W., Croll R.P. Modulation of in vivo neuronal sprouting by serotonin in the adult CNS of the snail. Cell Mol Neurobiol. 16:1996;561-576.
16. 3 receptor-active drugs alter development of spinal serotonergic innervation Lack of effect of other serotonergic agents . Brain Res. 571:1992;293-297.
17. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists Studies with microdialysis . Eur J Pharmacol. 200:1991;1-8.
18. Benloucif S., Keegan M.J., Galloway M.P. Serotonin-facilitated dopamine release in vivo Pharmacological characterization . J Pharmacol Exp Ther. 265:1993;373-377.
19. Bennett J.P. Jr, Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 36:1979;927-934.
20. Bennett-Clark C.A., Lane R.D., Rhoades R.W. Fenfluramine depletes serotonin from the developing cortex and alters thalamocortical organization. Brain Res. 702:1995;255-260.
21. Blandina S., Goldfarb J., Craddock-Royal B., Green J.P. Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in the striatum. J Pharmacol Exp Ther. 251:1989;803-809.
22. Bowers M.B. Jr, Heninger G.R., Gerbode F. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. Int J Neuropharmacol. 8:1969;255-262.
23. 2 receptor. Mol Pharmacol. 38:1990;604-609.
24. Breese G.R., Cooper B.R., Mueller R.A. Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Br J Pharmacol. 52:1974;307-314.
25. Breier A., Kirkpatrick B., Buchanan R.W. Clozapine attenuates metachlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry. 34:1993;492-494.
26. Brodie M.S., Bunney E.B. Serotonin potentiates dopamine inhibition of ventral tegmental area neurons in vitro. J Neurophysiol. 76:1996;2077-2082.
27. 1C receptor agonist. J Pharmacol Exp Ther. 258:1991;891-896.
28. Burt D.R., Creese I., Snyder S.H. Binding interactions of lysergic acid diethylamide and related agents with dopaminergic receptors in brain. Mol Pharmacol. 12:1976;631-638.
29. Cameron D.L., Wessendorf M.W., Williams J.T. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids. Neuroscience. 77:1997;155-166.
30. Carlsson A.J. Antipsychotic drugs and catecholamine synapses. Psychiatry Res. 11:1974;57-64.
31. Carroll M.E., Lac S.T., Asencio M., Kragh R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav. 35:1990;237-245.
32. Cerletti A., Rothlin E. Role of 5-hydroxytryptamine in mental disease and its antagonism to lysergic acid derivatives. Nature. 176:1955;785-786.
33. Ceulemans D.L., Gelders Y.G., Hoppenbrouwers M.L., Reyntjens A.J., Janssen P.A. Effect of serotonin antagonism in schizophrenia A pilot study with setoperone . Psychopharmacology (Berl). 85:1985;329-332.
34. 3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res. 543:1991;354-357.
35. Chen L., Hamaguchi K., Hamada S., Okado N. Regional differences of serotonin-mediated synaptic plasticity in the chicken spinal cord with development and aging. J Neural Transplant Plast. 6:1997;41-48.
36. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons . J Neurosci. 3:1983;1607-1619.
37. Chiodo L.A., Bunney B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neuro Neurosci. 5:1985;2539-2544.
38. Chubakov A.R., Gromova E.A., Konovalov G.V., Sarkisova E.F., Chumasov E.I. The effects of serotonin on the morpho functional development of rat cerebral neocortex in tissue culture. Brain Res. 369:1986;285-297.
39. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset. Br J Pharmacol. 92:1987;881-894.
40. Creese I., Burt D.R., Snyder S.H. The dopamine receptor Differential binding of d-LSD and related agents to agonist and antagonist states . Life Sci. 17:1976;1715-1720.
41. Crow T.J., Baker H.F., Cross A.J., et al. Monoamine mechanisms in chronic schizophrenia Post-mortem neurochemical findings . Br J Psychiatry. 134:1979;249-256.
42. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
43. De Belleroche J.S., Bradford H.F. Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes A comparison between the effect of 5-hydroxytryptamine, acetylcholine, and glutamate . J Neurochem. 35:1980;1227-1237.
44. 2 receptors in cerebral cortex. Neuropharmacology. 24:1985;947-952.
45. Deckert J., Catalano M., Heils A., et al. Functional promoter polymorphism of the human serotonin transporter Lack of association with panic disorder . Psychiatr Genet. 7:1997;45-47.
46. 1D receptors in human brain An autoradiographic study . Eur J Neurosci. 8:1996;53-60.
47. 3 antagonist, ondansetron, in schizophrenia. Meltzer H.Y. Novel Antipsychotic Drugs. 1992;225-232 Raven Press, New York.
48. DeVivo M., Maayani S. Characterization of the 5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampus membranes. J Pharmacol Exp Ther. 238:1986;248-253.
49. Dewey S.L., Smith G.S., Logan J., et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 15:1995;821-829.
50. Dray A., Gonye T.J., Oakley N.R., Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res. 113:1976;45-57.
51. Dray A., Davies J., Oakley N.R., Tongroach P., Velucci S. The dorsal and median raphe projections to the substantia nigra in the rat Electrophysiological, biochemical and behavioral observations . Brain Res. 151:1978;431-442.
52. Duinkerke S.J., Botter P.A., Jansen A.A., et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry. 163:1993;451-455.
53. Dumuis A., Sebben M., Bockaert J. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol Pharmacol. 33:1988;178-186.
54. Erdmann J., Shimron-Abarbanell D., Rietschel M., et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene Identification of two naturally occurring receptor variants and association analysis in schizophrenia . Hum Genet. 97:1996;614-619.
55. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 49:1992;538-544.
56. Farde L., Nordstrom A.L., Nyberg S., Halldin C., Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry. 55:1994;67-69.
57. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. Psychopharmacology (Berl). 15:1995;19S-23S.
58. Farley I.J., Shannak K.S., Hornykiewicz O. Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased receptor sensitivity. Pepeu G., Kuhar M.J., Enna S.J. Receptors for Neurotransmitters and Peptides. 1980;427-433 Raven Press, New York.
59. Fibiger H.C., Miller J.J. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience. 2:1977;975-987.
60. 2C receptors in the stimulus effects of hallucinogenic drugs I Antagonist correlation analysis . Psychopharmacology (Berl). 121:1995;347-356.
61. Freedman D.X. Effects of LSD-25 on brain serotonin. J Pharmacol Exp Ther. 134:1961;160-166.
62. Freedman D.X., Gottleib R., Lovell R.A. Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem Pharmacol. 19:1970;1181-1188.
63. Fuxe K., Holmstedt B., Jonsson G. Effects of 5-methoxy-N,N-dimethyltryptamine on central monoamine neurons. Eur J Pharmacol. 19:1972;25-34.
64. Gaddum J.H. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol. 121:1953;15P.
65. Gaddum J.H., Hameed K.A. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol. 9:1954;240-248.
66. 2 receptor indicates binding site structure. Med Chem Res. 3:1993;52-66.
67. 4 receptor antagonists. Med Res Rev. 17:1997;163-214.
68. Gelders Y.G. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry. 155:1989;33-36.
69. Gelernter J., Rao P.A., Pauls D.L., Hamblin M.W., Sibley D.R., Kidd K.K. Assignment of the 5HT7 receptor gene (HTR7) to chromosome 10q and exclusion of genetic linkage with Tourette syndrome. Genomics. 26:1995;207-209.
70. Gillies D.M., Mylecharane E.J., Jackson D.M. Effects of 5-HT3 receptor-selective agents on locomotor activity in rats following injection into the nucleus accumbens and the ventral tegmental area. Eur J Pharmacol. 6:1996;1-12.
71. Gillin J., Kaplan J., Wyatt R. Clinical efects of tryptophan in chronic schizophrenic patients. Biol Psychiatry. 11:1976;635-639.
72. 2 agonists or antagonists? Neuropsychopharmacology. 3:1990;509-517.
73. Glennon R.A., Young R., Rosecrans J.A. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol. 22:1983;189-196.
74. Glennon R.A., Young R., Hauck A.E., McKenney J.D. Structure activity studies on amphetamine analogues using drug discrimination methodology. Pharmacol Biochem Behav. 21:1984;895-901.
75. 2 involvement in the mechanism of action of hallucinogenic agents. Eur J Pharmacol. 35:1984;2505-2511.
76. Glennon R.A., Teitler M., Young R. Structure-activity relationships and mechanisms of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull. 22:1986;953-958.
77. Goldberg J.I., Mills L.R., Kater S.B. Novel effects of serotonin on neurite outgrowth in neurons cultured from embryos of Helisoma Trivolvis. J Neurobiol. 22:1990;182-194.
78. Gomes U.C., Shanley B.C., Potgieter L., Roux J.T. Noradrenergic overactivity in schizophrenia Evidence based on cerebrospinal fluids noradrenaline and cyclic nucleotide concentrations . Br J Psychiatry. 137:1980;346-351.
79. Gromova H.A., Chubakov A.R., Chumasov E.I., Konovalov H.V. Serotonin as a stimulator of hippocampal cell differentiation in tissue culture. J Dev Neurosci. 1:1983;339-349.
80. Guan X.M., McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull. 23:1989;541-547.
81. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxy methamphetamine Implications for serotonin-dopamine interactions . J Neurochem. 6:1996;243-249.
82. Gur R.E., Mozley P.D., Resnick S.M., et al. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry. 52:1995;657-667.
83. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain . Psychopharmacology (Berl). 124:1996;74-86.
84. Herve D., Pickel V.M., Joh T.H., Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat Fine structure and synaptic input to dopaminergic neurons . Brain Res. 1:1987;71-83.
85. Heuther G., Thomke F., Adler L. Administration of tryptophan-enriched diets to pregnant rats retards the development of the serotonergic system in their offspring. Dev Brain Res. 68:1992;175-181.
86. 1 recognition sites. J Recept Res. 8:1988;59-81.
87. Hsieh C.L., Bowcock A.M., Farrer L.A., et al. The serotonin receptor subtype 2 locus HTR2 is on human chromosome 13 near genes for esterase D and retinoblastoma-1 and on mouse chromosome 14. Somat Cell Mol Genet. 16:1990;567-574.
88. 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol. 238:1993;291-297.
89. Imai H., Steindler D.A., Kitai S.T. The organization of divergent axonal projections from the midbrain raphe nuclei in the rat. J Comp Neurol. 243:1986;363-380.
90. Iqbal N., Asnis G.M., Wetzler S., Kahn R.S., Kay S.R., van Praag H.M. The mCPP challenge test in schizophrenia Hormonal and behavioral responses . Biol Psychiatry. 30:1991;770-778.
91. 1C-selective antagonist. J Med Chem. 36:1993;2519-2525.
92. Iyer R.N., Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release Pharmacological characterization . J Pharmocol Exp Ther. 277:1996;40-47.
93. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
94. Jennings W.S., Schultz S.C., Narasimhachar N., et al. Brain ventricular size and CSF monoamine metabolite in an adolescent inpatient population. Psychiatry Res. 16:1984;87-94.
95. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
96. Kahn R.S., Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry. 30:1991;1139-1166.
97. Kahn R.S., Siever L.J., Gabriel S., et al. Serotonin function in schizophrenia Effects of metachlorophenylpiperazine in schizophrenic patients and healthy subjects . Psychiatry Res. 43:1992;1-12.
98. 2 receptor from a human to a rat pharmacology. FEBS Lett. 307:1992;324-328.
99. 2 antagonism and EPS benefits Is there a causal connection? Psychopharmacology (Berl). 124:1996;35-39.
100. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
101. Kasapi M., Holik J., Shah M., Hoff M., Coon H., Byerley W. SSCP at the HTR1DA locus. Hum Mol Genet. 3:1994;1444.
102. Kelland M.D., Freeman A.S., Chiodo L.A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther. 253:1990;803-811.
103. 2C/2B receptor antagonist. Br J Pharmacol. 111:1994;797-802.
104. Khan M.A., Isenberg K.E., Aschauer H., Devor E.J. A Sac I RFLP is detected with the 5-HT1a serotonin receptor probe G21. Nucl Acids Res. 3:1990;691.
105. 6 serotonin receptor. J Neurochem. 66:1996;47-56.
106. Koreen A.R., Lieberman J.A., Alvir J., Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychopharmacology. 16:1997;61-68.
107. Kosofsky B.E., Molliver M.E. The serotoninergic innervation of cerebral cortex Different classes of axon terminals arise from dorsal and median raphe nuclei . Synapse. 1:1987;153-168.
108. Krystal J.H., Seibyl J.P., Price L.H., et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry. 50:1993;624-635.
109. Lappalainen J., Dean M., Charbonneau L., Virkkunen M., Linnoila M., Goldman D. Mapping of the serotonin 5-HT1D beta autoreceptor gene on chromosome 6 and direct analysis for sequence variants. Am J Med Genet. 60:1995;157-161.
110. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry. 50:1993;810-818.
111. Lauder J.M. Ontogeny of the serotonin sytem in the rat Serotonin as a developmental signal . Ann NY Acad Sci. 600:1990;297-313.
112. Lauder J.M. Ontogeny of neurotransmitter systems Substrates for developmental disabilities . Ment Retard Dev Disabil Res Rev. 1:1995;51-168.
113. Lauder J.M., Liu J. Glial heterogeneity and developing neurotransmitter systems. Perspect Dev Neurobiol. 2:1994;239-250.
114. Lavoie B., Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol. 299:1990;1-16.
115. Leccese A.P., Lyness W.H. The effects of putative 5-hydroxytryptamine receptor active agents on d-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. Brain Res. 303:1984;153-162.
116. Leonard B.E. Some effects of of the hallucinogenic drug 2,5-dimethoxy-4-methylamphetamine on the metabolism of biogenic amines in the rat brain. Psychopharmacologia. 32:1973;33-49.
117. Leysen J.E. Serotonin receptor binding sites. Green A.R. Neuropharmacology of Serotonin. 1985;86-87 Oxford University Press, Oxford.
118. Losonczy M.F., Song I.S., Mohs R.C., et al. Correlates of lateral ventricular size in chronic schizophrenia, II Biological measures . Am J Psychiatry. 143:1986;1113-1118.
119. Mabry P.D., Campbell B.A. Serotonergic inhibition of catecholamine-induced behavioral arousal. Brain Res. 49:1973;381-391.
120. 2-adrenoceptor agonists and antagonists . Psychopharmacology (Berl). 120:1995;384-391.
121. 2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat. Neuropharmacology. 10:1997;1471-1478.
122. 2A receptor and response to clozapine. Lancet. 346:1995;1108.
123. Mazer C., Muneyyirci J., Taheny K., Raio N., Borella A., Whitaker-Azmitia P. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat A possible model of neurodevelopmental disorders with cognitive deficits . Brain Res. 760:1997;68-73.
124. 2 receptor . Biol Psychiatry. 26:1989;297-302.
125. McKenna D.J., Saavedra J.M. Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain. Eur J Pharmacol. 142:1987;313-315.
126. McKenna D.J., Repke D.B., Peroutka S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 29:1990;193-198.
127. Meert T.F., De Haes P.L.A.J., Vermote P.C.M. The discriminative stimulus properties of LSD Serotonergic and catecholaminergic interactions . Psychopharmacology (Berl). 101:1990;271.
128. 3H]LSD binding by rat brain slices in vitro The effect of 5-hydroxytryptamine . Eur J Pharmacol. 67:1980;371-382.
129. 2A pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
130. 2 antagonist ritanserin. Psychopharmacol Bull. 26:1990;373-376.
131. Morand C., Yong S., Ervin F. Clinical response of aggressive schizophrenics to oral tryptophan. Biol Psychiatry. 18:1983;575-578.
132. Morrow B.A., Roth R.H. Serotonergic lesions alter cocaine-induced locomotor behavior and stress-activation of the mesocorticolimbic dopamine system. Synapse. 23:1996;174-181.
133. Mylecharane E.J. Ventral tegmental area 5-HT receptors Mesolimbic dopamine release and behavioural studies . Behav Brain Res. 73:1996;1-5.
134. Nash J.F. Ketanserin pretreatment attenuates MDMA-induced DA release in the striatum as measured by in-vivo microdialysis. Life Sci. 47:1990;2401-2408.
135. Nash J.F., Nichols D.E. Microdialysis studies of 3,4-methylenedioxymethamphetamine and structurally related analogues. Eur J Pharmacol. 200:1991;53-58.
136. 3H]Lysergic acid diethylamide (LSD) Differential agonist and antagonist binding properties at 5-HT receptor subtypes in rat brain . Neurochem Int. 14:1989;497-504.
137. Norman R.M., Malla A.K., Morrison-Stewart S.L., et al. Neuropsychological correlates of syndromes in schizophrenia. Br J Psychiatry. 170:1997;134-139.
138. Nothen M.M., Erdmann J., Shimron-Abarbanell D., Propping P. Identification of genetic variation in the human serotonin 1D beta receptor gene. Biochem Biophys Res Commun. 205:1994;1194-1200.
139. Nyberg S., Farde L., Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
140. Osterheld-Haas M.C., Hornung J.P. Laminar development of the mouse barrel cortex Effects of neurotoxins against monoamines . Exp Brain Res. 110:1996;183-195.
141. Owen F., Cross A.J., Crow T.J., Lofthouse R., Poulter M. Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand. 63:1981;20-28.
142. Owen R.R. Jr, Gutierrez-Esteinou R., Hsiao J., et al. Effects of clozapine and fluphenazine treatment on response to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry. 50:1993;636-644.
143. Ozaki N., Lappalainen J., Dean M., Virkkunen M., Linnoila M., Goldman D. Mapping of the serotonin 5-HT1D alpha autoreceptor gene (HTR1D) on chromosome 1 using a silent polymorphism in the coding region. Am J Med Genet. 60:1995;162-164.
144. Parsons L.H., Justice J.B. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 606:1993;195-199.
145. Pehek E.A. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse. 24:1996;12-28.
146. Pickar D., Roy A., Breier A., Doran A., Wolkowitz O., Colison J., et al. Suicide and aggression in schizophrenia Neurobiologic correlates . Ann NY Acad Sci. 487:1986;189-196.
147. Pierce P.A., Peroutka S.J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl). 97:1989;118-122.
148. 2 receptors. Neuropsychopharmacology. 3:1990;503-508.
149. Potkin S., Weinberger D.R., Linnoila M. Low CSF 5-hydroxyindoleacetic acid in schizophrenic brains with enlarged ventricles. Am J Psychiatry. 140:1983;21-25.
150. Randic M., Padjen A. Effect of N,N-dimethyltryptamine and d-lysergic acid diethylamide on the release of 5-hydroxyindoles in rat forebrain. Nature. 230:1971;532-533.
151. Randrup A., Munkvad I. Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities. Psychopharmacologia. 7:1965;416-422.
152. Reynetjens A., Gelders M.L., Hoppenbrouwers J.A., Bussche G.V. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res. 8:1986;205-211.
153. Rhoades R.W., Bennett-Clarke C.A., Shi M.Y., Mooney R.D. Effects of 5-HT on thalamocortical synaptic transmission in the developing rat. J Neurophysiol. 72:1994;2438-2450.
154. 1A receptor agonists on septal cholenergic neurons in culture. Dev Brain Res. 82:1994;245-258.
155. Richardson N.R., Roberts D.C.S. Fluoxetine pretreatment reduces breaking points on a progressive ration schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci. 49:1991;833-840.
156. Rogawski M.A., Aghajanian G.K. Response of central monoaminergic neurons to lisuride Comparison with LSD . Life Sci. 24:1979;1289-1298.
157. Rogue A, Rogue P (1992): Mianserin in the management of schizophrenia. In: Schizophrenia, an International Conference Abstract Book, Vancouver BC, p 135.
158. Rorig B., Sutor B. Serotonin regulates gap junction coupling in the developing rat somatosensory cortex. Eur J Neurosci. 8:1996;1685-1695.
159. Rosecrans J.A., Lovell R.A., Freedman D.X. Effects of lysergic acid diethylamide on the metabolism of brain 5-hydroxytryptamine. Biochem Pharmacol. 16:1967;2011-2021.
160. Rouillard C., Bovetto S., Gervais J., Richard D. Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum Possible interaction between serotonin and dopamine . Mol Brain Res. 37:1996;105-115.
161. 2 receptors Implications for treating LSD-induced hallucinogenesis . Psychopharmacology (Berl). 98:1989;495-499.
162. 1C receptor agonists What next? Lin G.C., Glennon R.A. Hallucinogens An Update . 1994;203-213 US-DHHS, Rockville, MD. (NIDA Research Monograph Series 146.).
163. 1C receptor activation by hallucinogenic drugs . Psychopharmacology (Berl). 105:1991;340-346.
164. Sanders-Bush E., Burris K.D., Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther. 246:1988;924-928.
165. 2A receptor antagonist MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol. 273:1995;273-279.
166. Schmidt C.J., Levin J.A., Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol. 187:1987;747-755.
167. Schmidt C.J., Black C.K., Taylor V.L. Antagonism of the neurotoxicity due to a single administration of 3,4-methylenedioxymethamphetamine. Eur J Pharmacol. 181:1990;59-70.
168. 2 receptors exert a state-dependent regulation of dopaminergic function Studies with MDL 199,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine . Eur J Pharmacol. 223:1992;65-74.
169. 2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
170. Schreiber R., Brocco M., Millan M.J. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol. 264:1994;99-102.
171. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
172. Shimron-Abarbanell D., Harms H., Erdmann J., et al. Systematic screening for mutations in the human serotonin 1F receptor gene in patients with bipolar affective disorder and schizophrenia. Am J Med Genet. 67:1996;225-228.
173. Shore D., Korpi E.R., Bigelow L.B., Zec R.F., Wyatt R.J. Fenfluramine and chronic schizophrenia. Biol Psychiatry. 20:1985;329-352.
174. Sidenberg D.G., Bassett A.S., Demchyshyn L., et al. New polymorphism for the human serotonin 1D receptor variant (5-HT1D beta) not linked to schizophrenia in five Canadian pedigrees. Hum Hered. 43:1993;315-318.
175. Siegel B.V. Jr, Buchsbaum M.S., Bunney W.E. Jr, et al. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry. 150:1993;1325-1336.
176. Smith G.S., Dewey S.L., Brodie J.D., et al. Serotonergic modulation of dopamine measured with [11C] raclopride and PET in normal human subjects. Am J Psychiatry. 154:1997;490-496.
177. Snyder S., Greenberg D., Yamamura H.I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 31:1974;58-61.
178. Sodhi M.S., Arranz M.J., Curtis D., et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. 7:1995;169-172.
179. Soper H.V., Elliott R.O., Rejzer A.A., Marshall B.D. Jr. Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients. J Clin Psychopharmacol. 10:1990;168-175.
180. 2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine syntheses. J Pharmacol ExpTher. 260:1992;872-878.
181. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic Behavioral, electrophysiological and neurochemical studies . J Pharmacol Exp Ther. 266:1993;684-691.
182. 1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur J Neurosci. 2:1990;1144-1154.
183. Stahl S.M., Uhr S.B., Berger P.A. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic patients. Biol Psychiatry. 20:1985;1098-1102.
184. 3H]-monoamines into synaptosomes from different regions of the rat brain. Biochem Pharmacol. 36:1987;2297-2303.
185. Steinbusch H.W.M., Niewenhuys R., Verhofstad A.A.J., Van der Kooy D. The nucleus raphe dorsalis of the rat and its projection upon the caudate-putamen. A combined cytoarchitectonic immunocytochemical and retrograde transport study. J Physiol. 77:1981;157-174.
186. 2 receptor and alpha 1-adrenoceptor antagonism . J Clin Psychopharmacol. 15:1995;11S-18S.
187. 3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA Evidence for multiple states and not multiple 5HT2 receptor subtypes . Mol Pharmacol. 38:1990;594-598.
188. 2 receptor as site of action for LSD and phenylisopropylamine halucinogens. Psychopharmacology (Berl). 94:1988;213-216.
189. Twarog B.M., Page I. Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol. 175:1953;157-161.
190. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl). 98:1989;45-50.
191. U'Prichard D.C., Greenberg D.A., Snyder S.H. Binding characteristics of radiolabeled agonists and antagonists at central nervous system alpha noradrenergic receptors. Mol Pharmacol. 13:1977;454-473.
192. Van Bockstaele E.J., Cestari D.M., Pickel V.M. Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area Potential sites for mudulation of mesolimbic dopamine neurons . Brain Res. 647:1994;307-322.
193. Van der Kooy D., Hattori D. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra A fluorescent retrograde double labeling study in the rat . Brain Res. 186:1980;1-7.
194. Wallace J.A., Lauder J.M. Development of the serotonergic system in the rat embryo An immunocytochemical study . Brain Res Bull. 10:1983;459-479.
195. 3-like receptors . Behav Brain Res. 73:1996;7-10.
196. Warren J.T. Jr, Peacock M.L., Rodriguez L.C., Fink J.K. An MspI polymorphism in the hyman serotonin receptor gene (HTR2) Detection by DGGE and RFLP analysis . Hum Mol Genet. 2:1993;338.
197. 1 dopamine receptors . Psychopharmacology (Berl). 118:1995;401-409.
198. Weinberger D.R., Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia A search for common ground . Schizophr Res. 16:1995;87-110.
199. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III A new cohort and evidence for a monoaminergic mechanism . Arch Gen Psychiatry. 45:1988;609-615.
200. Whitaker P.M., Crow T.J., Ferrier I.N. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry. 38:1981;278-280.
201. Whitaker-Azmitia P.M., Clarke C., Azmitia E.C. Localization of 5-HT1A receptors to astroglial cells in adult rats Implications for neuronal-glial interactions psychoactive drug mechanism of action . Synapse. 14:1993;201-205.
202. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 221:1983;1054-1057.
203. White F.J., Wang R.Y. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci. 32:1983;983-993.
204. Wiesel, Nordstrom A.-L., Farde L., Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl). 114:1994;31-38.
205. Williams J.T., Colmers W.F., Pan Z.Z. Voltage and ligand activated inwardly rectifying currents in rat dorsal raphe neurons in vitro. J Neurosci. 8:1988;3499-3506.
206. Williams J., Spurlock G., McGuffin P., et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene [European Multicentre Association Study of Schizophrenia (EMASS) Group]. Lancet. 347:1996;1294-1296.
207. Winblad B., Bucht G., Gottfries C.G., Roos B.E. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr Scand. 60:1979;17-28.
208. Wode-Helgodt B., Fyro B., Gullberg B., Sedvall G. Effect of chlorpromazine treatment on monamine metabolite levels in cerebrospinal fluids on psychotic patients. Acta Psychiatr Scand. 56:1977;280-293.
209. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA. 40:1954;228-231.
210. Zhou F.C., Bledsoe S., Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556:1991;108-116.